Plexiform Neurofibroma clinical trials at University of California Health
2 in progress, 1 open to eligible people
Experimental MEK Inhibitor Mirdametinib (PD-0325901) for Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
open to eligible people ages 2 years and up
This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901).
at UC Davis UC Irvine UCLA
Sorry, in progress, not accepting new patients
This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib. The primary objective is to determine if there is an adequate level of disease responsiveness to binimetinib in children and adults with NF1 and inoperable plexiform neurofibromas. The objective response to binimetinib is defined as ≥ 20% decrease in tumor volume reduction by 12 courses.
at UCLA UCSD UCSF